Drugs / co.don chondrosphere®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01222559 | Oct 2010 → Sep 2017 | — | co.don AG | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01225575 Comparator | Oct 2010 → Sep 2013 | — | co.don AG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | co.don chondrosphere | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01222559 ↗ |
| Known as | ACT3D-CS | “the autologous chondrocyte transplantation product co.don chondrosphere® (ACT3D-CS) in subjects with cartilage defects of the knee.” NCT01225575 ↗ |
| Modality | Cell therapy | “co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.” NCT01222559 ↗ |
| Route | Other | “that are transplanted in an open knee procedure (treatment surgery)into the defect.” NCT01222559 ↗ |